Elutia, Inc. (ELUT)
0.8392
+0.02
(+2.34%)
USD |
NASDAQ |
Nov 16, 13:48
Elutia Enterprise Value : 23.34M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 23.34M |
| November 12, 2026 | 25.95M |
| November 11, 2026 | 27.78M |
| November 10, 2026 | 28.36M |
| November 09, 2026 | 24.05M |
| November 06, 2026 | 24.12M |
| November 05, 2026 | 20.28M |
| November 04, 2026 | 20.66M |
| November 03, 2026 | 23.04M |
| November 02, 2026 | 23.39M |
| October 30, 2026 | 24.10M |
| October 29, 2026 | 23.06M |
| October 28, 2026 | 24.23M |
| October 27, 2026 | 22.67M |
| October 26, 2026 | 22.37M |
| October 23, 2026 | 24.12M |
| October 22, 2026 | 25.19M |
| October 21, 2026 | 23.47M |
| October 20, 2026 | 22.92M |
| October 19, 2026 | 23.13M |
| October 16, 2026 | 22.19M |
| October 15, 2026 | 21.96M |
| October 14, 2026 | 19.57M |
| October 13, 2026 | 21.27M |
| October 12, 2026 | 21.88M |
| Date | Value |
|---|---|
| October 09, 2026 | 23.48M |
| October 08, 2026 | 23.67M |
| October 07, 2026 | 23.35M |
| October 06, 2026 | 21.43M |
| October 05, 2026 | 23.42M |
| October 02, 2026 | 21.51M |
| October 01, 2026 | 22.46M |
| September 30, 2026 | 22.01M |
| September 29, 2026 | 25.84M |
| September 28, 2026 | 26.77M |
| September 25, 2026 | 27.20M |
| September 24, 2026 | 27.66M |
| September 23, 2026 | 29.35M |
| September 22, 2026 | 26.78M |
| September 21, 2026 | 28.69M |
| September 18, 2026 | 28.54M |
| September 17, 2026 | 28.54M |
| September 16, 2026 | 26.77M |
| September 15, 2026 | 26.33M |
| September 14, 2026 | 25.66M |
| September 11, 2026 | 26.77M |
| September 10, 2026 | 26.34M |
| September 09, 2026 | 26.33M |
| September 08, 2026 | 27.66M |
| September 04, 2026 | 27.27M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 487.93M |
| Amgen, Inc. | 292.70B |
| Anika Therapeutics, Inc. | 160.67M |
| BioCryst Pharmaceuticals, Inc. | 2.402B |
| Imunon, Inc. | 6.805M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.503M |
| Revenue (Quarterly) | 1.137M |
| Total Expenses (Quarterly) | 7.64M |
| EPS Diluted (Quarterly) | -0.1468 |
| Gross Profit Margin (Quarterly) | 61.74% |
| Profit Margin (Quarterly) | -571.9% |
| Earnings Yield | -75.26% |
| Normalized Earnings Yield | -67.25 |